Author:
Goshe Brett M.,Rasmussen Autumn W.,Wagner Lynne I.,Sicks JoRean D.,Gareen Ilana F.,Carlos Ruth C.,Herman Benjamin A.,Walter Angela Wangari,Regan Susan,Levy Douglas E.,Mahon Irene,Muzikansky Alona,Neil Jordan M.,Lui Michelle,Dilip Deepika,Malloy Laura,Gonzalez Irina,Finkelstein-Fox Lucy,McCann Caitlin,Perez Elissa,Ostroff Jamie S.,Park Elyse R.
Abstract
Abstract
Background
Persistent smoking among patients diagnosed with cancer is associated with adverse clinical outcomes, yet an evidence-based tobacco use intervention has not been well-integrated into cancer care in community oncology settings. This paper describes the protocol of a nation-wide clinical trial conducted by the ECOG-ACRIN National Cancer Institute (NCI) Community Oncology Research Program (NCORP) Research Base to assess the effectiveness of a virtual tobacco treatment intervention and the process of implementing tobacco treatment in NCORP community oncology settings.
Methods/design
This two-arm, multisite (n: 49 NCORP sites) hybrid type 1 effectiveness-implementation randomized controlled trial compares the effectiveness of a Virtual Intervention Treatment (VIT) versus an Enhanced Usual Control (EUC) among English and Spanish speaking patients recently diagnosed with cancer, reporting current smoking and receiving care at a participating NCORP Community or Minority/Underserved Site. The VIT includes up to 11 virtual counseling sessions with a tobacco treatment specialist and up to 12 weeks of nicotine replacement therapy (NRT). The EUC arm receives a referral to the NCI Quitline. The primary study outcome is biochemically confirmed 7-day point prevalence smoking abstinence. Moderators of treatment effect will be assessed. The study evaluates implementation processes from participating NCORP site staff via survey, administrative, and focus group data, including reach, acceptability, appropriateness, fidelity, feasibility, adoption, cost and sustainability outcomes.
Discussion
This trial will generate findings about the effectiveness of an evidence-based virtual tobacco treatment intervention targeting patients diagnosed with cancer and illuminate barriers and facilitators that influence implementing tobacco treatment into community oncology settings nationally. In the era of COVID-19, virtual care solutions are vital for maximizing access and utilization of tobacco treatment delivery.
Trial registration
ClinicalTrials.gov (NCT03808818) on January 18th, 2019; Last update posted: May 21st, 2020.
Funder
National Cancer Institute
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Reference73 articles.
1. Garces YI, Yang P, Parkinson J, et al. The relationship between cigarette smoking and quality of life after lung cancer diagnosis. Chest. 2004;126(6):1733–41. https://doi.org/10.1378/chest.126.6.1733.
2. Gritz ER, Toll BA, Warren GW. Tobacco use in the oncology setting: advancing clinical practice and research. Cancer Epidemiology, Biomarkers & Prevention. 2014;23(1):3–9. https://doi.org/10.1158/1055-9965.EPI-13-0896.
3. Park ER, Japuntich SJ, Rigotti NA, et al. A snapshot of smokers after lung and colorectal cancer diagnosis. Cancer. 2012;118(12):3153–64. https://doi.org/10.1002/cncr.26545.
4. Bellizzi KM, Rowland JH, Jeffery DD, McNeel T. Health behaviors of cancer survivors: examining opportunities for cancer control intervention. J Clin Oncol. 2005;23(34):8884–93. https://doi.org/10.1200/JCO.2005.02.2343.
5. National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Centers for Disease Control and Prevention (US); 2014. Accessed 28 Dec 2021. http://www.ncbi.nlm.nih.gov/books/NBK179276/